CHasing Expedited and Equitable Treatment Access
CHEETA will accelerate pediatric drug development and optimization and access to the best available treatments for children with tuberculosis (TB).
1.3 million
children fell ill with TB worldwide in 2023
TB by the Numbers
(Source: WHO)
2 in 5
people with drug resistant TB accessed treatment in 2023
1.25 million
people died from TB in 2023
CHEETA exists to accelerate pediatric drug development and access to the best available treatment for children with TB
CHEETA stands for Chasing Expedited and Equitable Treatment Access for Children
The aim of CHEETA is to accelerate pediatric development and optimization of TB medications to eliminate the existing 8-to-13-year delays for children compared to adults for accessing new TB drugs
CHEETA will foster strong partnerships with global health stakeholders, affected communities, and engage early with pharmaceutical innovators to advise on pediatric trial design and pediatric investigational plans
CHEETA is advancing optimized designs of phase I/II pediatric trials focused on pharmacokinetics, dose-finding, and safety of antituberculosis drugs in children to support innovators to efficiently advance regulatory filings and normative agencies and national governments to issue guidelines
CHEETA will explore innovative approaches including a platform trial to to more efficiently advance pediatric investigations of new TB compounds
CHEETA will expand global trial site capacity and build a sustainable research infrastructure that supports ongoing and future pediatric TB drug evaluations
CHEETA will ensure that children in high TB burden settings are not left behind